FLAP

5-lipoxygenase-activating protein; 5-LO activating protein

FLAP (Arachidonate 5-lipoxygenase-activating protein) is a protein that in humans is encoded by the ALOX5AP gene. FLAP is necessary for the activation of 5-lipoxygenase and therefore for the production of leukotrienes. It is an integral protein within the nuclear membrane. FLAP is necessary in synthesis of leukotriene, which are lipid mediators of inflammation that is involved in respiratory and cardiovascular diseases. FLAP functions as a membrane anchor for 5-lipooxygenase and as an amine acid-bind protein. Gene polymorphisms in FLAP are suspected of playing a role in Alzheimer's disease. Leukotrienes, which need the FLAP protein to be made, have an established pathological role in allergic and respiratory diseases. Animal and human genetic evidence suggests they may also have an important role in atherosclerosis, myocardial infarction, and stroke. The structure of FLAP provides a tool for the development of novel therapies for respiratory and cardiovascular diseases and for the design of focused experiments to probe the cell biology of FLAP and its role in leukotriene biosynthesis.

FLAP Inhibitors

(S)-BI 665915

Cat. No.: HY-12995A

(S)-BI 665915 is an orally active oxadiazole-containing **5-lipoxygenase-activating protein (FLAP)** inhibitor with an IC_{50} of 1.7 nM for FLAP binding. (S)-BI 665915 inhibits FLAP functional in human whole blood with an IC_{50} of 45 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AM103

Cat. No.: HY-14163

AM 103 is a potent and selective **FLAP** inhibitor, with an IC_{50} value of 4.2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AM679

Cat. No.: HY-14460

AM679 is a potent, selective **5-lipoxygenase-activating protein (FLAP)** inhibitor with an IC_{50} of 2 nM in a human FLAP membrane binding assay.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD5718

Cat. No.: HY-122908

AZD5718 is an orally active inhibitor of **FLAP (5Lipoxygenase activating protein)**, with an IC_{50} of 2 nM. AZD5718 is used in the study for coronary artery disease.



Purity: 98.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Diflapolin

Cat. No.: HY-128171

Diflapolin is a highly active dual 5-lipoxygenase-activating protein **(FLAP)**/soluble epoxide hydrolase **(sEH)** inhibitor with marked anti-inflammatory efficacy and high target selectivity.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fiboflapon

(GSK2190915; AM-803)

Cat. No.: HY-15874

Fiboflapon (GSK2190915; AM-803) is a potent and orally bioavailable 5-lipoxygenase-activating protein (**FLAP**) inhibitor with a potency of 2.9 nM in FLAP binding, an IC_{50} of 76 nM for inhibition of **LTB4** in human blood.



Purity: 98.18%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Fiboflapon sodium

(GSK2190915 sodium salt; AM-803 sodium)

Cat. No.: HY-15874A

Fiboflapon sodium (GSK2190915; AM-803) is a potent and orally bioavailable 5-lipoxygenase-activating protein (**FLAP**) inhibitor with a potency of 2.9 nM in FLAP binding, an IC_{50} of 76 nM for inhibition of **LTB4** in human blood.



Purity: 99.08%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

MK-886

(L 663536)

Cat. No.: HY-14166

MK-886 (L 663536) is a potent, cell-permeable and orally active **FLAP** (IC_{50} of 30 nM) and **leukotriene biosynthesis** (IC_{50}s of 3 nM and 1.1 μM in intact leukocytes and human whole blood, respectively) inhibitor. MK-886 is also a non-competitive **PPARα** antagonist and can induce **apoptosis**.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Quiflapon

(MK-591)

Cat. No.: HY-10037

Quiflapon (MK-591) is a selective and specific **5-lipoxygenase-activating protein (FLAP)** inhibitor with an IC_{50} of 1.6 nM in a FLAP binding assay.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Quiflapon sodium

(MK-591 sodium)

Cat. No.: HY-50714

Quiflapon sodium (MK-591 sodium) is a selective and specific 5-Lipoxygenase-activating protein (**FLAP**) inhibitor. Quiflapon sodium is an orally active **Leukotriene biosynthesis** inhibitor. Induces **apoptosis**.



Purity: 98.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Veliflapon

(BAY X 1005; DG-031) **Cat. No.**: HY-14165

Veliflapon (BAY X 1005; DG-031) is an orally active and selective **5-lipoxygenase activating protein (FLAP)** inhibitor. Veliflapon inhibits the synthesis of the **leukotrienes B4** and **C4**.



Purity: ≥99.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg